Clinical trial escrow models immobilize $15–25M per $100M portfolio in capital that earns no research return. ClinTrust.ai's dynamic funding model changes that structurally.
Adjust the parameters below to model capital efficiency gains for your trial portfolio.
A representative analysis of capital efficiency impact for a mid-size pharma sponsor running a $100M annual trial payment portfolio across 12 sites in APAC.
How the same $100M portfolio's capital is deployed under each model.
ClinTrust.ai's dynamic funding model is calibrated to actual trial execution velocity — not to conservative worst-case assumptions.
The system models actual payment outflow rates based on enrolled patient counts, visit schedules, and historical execution rates for each site. This produces a statistically sufficient minimum buffer — not a padded estimate.
When the buffer reaches a pre-configured threshold (e.g., falls below 30 days of projected payments), an automated replenishment request is issued to the sponsor. Capital is committed only when the pipeline requires it.
The model includes a statistical overage factor for visit completion surges, amendment-driven rate changes, and milestone payments — ensuring buffers are never depleted even in accelerated enrollment scenarios.
Sponsors have real-time visibility into buffer levels, projected depletion timelines, upcoming replenishment requirements, and cumulative capital efficiency versus the traditional escrow baseline.
Our capital efficiency team will model the specific savings opportunity for your trial portfolio — with a detailed breakdown by study, site, and escrow structure.